From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor γ modulators
Open Access
- 1 January 2010
- journal article
- review article
- Published by Elsevier BV in The American Journal of Clinical Nutrition
- Vol. 91 (1), 251S-253S
- https://doi.org/10.3945/ajcn.2009.28449a
Abstract
Type 2 diabetes is a complex disease that requires long-term therapy aimed at multiple targets. At Experimental Biology 2009 (www.eb2009.org), held last April in New Orleans, LA, the American Society for Nutrition hosted the symposium “From bench to bedside: novel therapeutic advances through the development of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.” Presenters addressed the latest science on novel pathways that regulate metabolism and insulin resistance, including fibroblast growth factor 21 (FGF21) and adiponectin, as well as advances in our understanding of the biology of PPARγ, including modes of action and recently discovered side effects of PPARγ agonists. They also explored the pharmacologic and physiologic actions of FGF21 and adiponectin, metabolic regulators that could provide novel therapeutic opportunities in the future, as well as current data on selective PPARγ modulators. These molecules offer a new direction in the search for more specific PPARγ activators that will retain efficacy for the treatment of diabetes without major side effects.This publication has 21 references indexed in Scilit:
- Peroxisome proliferator-activated receptor translational research and clinical experienceThe American Journal of Clinical Nutrition, 2010
- Selective peroxisome proliferator-activated receptor γ (PPARγ) modulation as a strategy for safer therapeutic PPARγ activationThe American Journal of Clinical Nutrition, 2010
- Adiponectin in insulin resistance: lessons from translational researchThe American Journal of Clinical Nutrition, 2010
- Relationship between peroxisome proliferator-activated receptor-γ activation and the ameliorative effects of ascochlorin derivatives on type II diabetesThe Journal of Antibiotics, 2009
- Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease – Future Promise, Present FearsNephron Clinical Practice, 2009
- Fibroblast Growth Factor 21 Controls Glycemia via Regulation of Hepatic Glucose Flux and Insulin SensitivityEndocrinology, 2009
- MBX-102/JNJ39659100, a Novel Non-TZD Selective Partial PPAR- Agonist Lowers Triglyceride Independently of PPAR- ActivationPPAR Research, 2009
- INT131: A Selective Modulator of PPARγJournal of Molecular Biology, 2009
- The Development of INT131 as a Selective PPAR Modulator: Approach to a Safer Insulin SensitizerPPAR Research, 2008
- Selective Modulators of PPAR-Activity: Molecular Aspects Related to Obesity and Side-EffectsPPAR Research, 2007